<code id='870CF8EB81'></code><style id='870CF8EB81'></style>
    • <acronym id='870CF8EB81'></acronym>
      <center id='870CF8EB81'><center id='870CF8EB81'><tfoot id='870CF8EB81'></tfoot></center><abbr id='870CF8EB81'><dir id='870CF8EB81'><tfoot id='870CF8EB81'></tfoot><noframes id='870CF8EB81'>

    • <optgroup id='870CF8EB81'><strike id='870CF8EB81'><sup id='870CF8EB81'></sup></strike><code id='870CF8EB81'></code></optgroup>
        1. <b id='870CF8EB81'><label id='870CF8EB81'><select id='870CF8EB81'><dt id='870CF8EB81'><span id='870CF8EB81'></span></dt></select></label></b><u id='870CF8EB81'></u>
          <i id='870CF8EB81'><strike id='870CF8EB81'><tt id='870CF8EB81'><pre id='870CF8EB81'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:leisure time    Page View:56358
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In